Pilon D

Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Suite 1500, Montréal, QC, H3B 0G7, Canada.

8 papers · ORCID

ArticleKetamine

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Clemens K, Zhdanava M, Teeple A +6

Europe PMC2025
ArticleKetamine

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Clemens K, Teeple A, Zhdanava M +6

Europe PMC2025
ArticleKetamine

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.

Jha MK, Zhdanava M, Shah A +4

Europe PMC2025
ArticleKetamine

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Harding L, Zhdanava M, Teeple A +4

Europe PMC2025
ArticleKetamine

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Clemens K, Zhdanava M, Teeple A +5

Europe PMC2025
ArticleKetamine

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.

Harding L, Zhdanava M, Shah A +5

Europe PMC2024
ArticleKetamine

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.

Teeple A, Zhdanava M, Pilon D +3

Europe PMC2023
ArticleKetamine

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Zhdanava M, Teeple A, Pilon D +3

Europe PMC2023